The Somewhat Favorable Press Coverage Extremely Likely to Impact Stemline Therapeutics (STML) Stock Price

The Somewhat Favorable Press Coverage Extremely Likely to Impact Stemline Therapeutics (STML) Stock Price

Here are some of the news headlines that may have impacted Alpha One Sentiment Analysis’s rankings:

Press coverage about Stemline Therapeutics (NASDAQ:STML) has been trending somewhat positive recently, AlphaOne Sentiment reports. The research group, a service of Accern, scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Stemline Therapeutics earned a media sentiment score of 0.20 on AlphaOne’s scale. AlphaOne also gave news headlines about the biopharmaceutical company an impact score of 96 out of 100, meaning that recent media coverage is extremely likely to have an impact on the company’s share price in the next several days.

A number of analysts have recently issued reports on STML shares. HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Stemline Therapeutics in a research note on Tuesday, March 28th. Cowen and Company reissued a “buy” rating on shares of Stemline Therapeutics in a research note on Friday, May 12th. Ladenburg Thalmann Financial Services set a $41.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Monday, March 20th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Stemline Therapeutics in a research note on Thursday, May 25th. Finally, Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, February 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $29.17. Stemline Therapeutics (NASDAQ:STML) opened at 7.95 on Monday. Stemline Therapeutics has a one year low of $5.50 and a one year high of $14.60. The firm has a 50-day moving average of $8.41 and a 200-day moving average of $9.63. The company’s market capitalization is $185.84 million.

Stemline Therapeutics Company Profile Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:STML”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Stemline Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Stemline Therapeutics Inc and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment